(105 days)
Not Found
No
The description focuses on a mechanical thrombectomy catheter using saline jets and suction, with no mention of AI, ML, or related concepts.
Yes
The device is intended to break apart and remove thrombus from blood vessels, which is a therapeutic intervention for medical conditions like thrombosis.
No
This device is a thrombectomy catheter, used to remove thrombus. Its function is interventional/therapeutic, not diagnostic.
No
The device description clearly describes a physical catheter and its mechanism of action involving saline jets, indicating it is a hardware device.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are medical devices used to perform tests on samples taken from the human body (like blood, urine, tissue) to provide information about a person's health. These tests are performed outside the body (in vitro).
- Device Description: The AngioJet XPEEDIOR 120 Rheolytic Thrombectomy Catheter is described as a device that uses high-velocity saline jets to break up and remove thrombus within the body (percutaneously). This is an interventional procedure performed in vivo.
- Intended Use: The intended use is to remove thrombus from arteries and veins, which are structures within the body.
The function and application of this device clearly fall outside the scope of in vitro diagnostics.
N/A
Intended Use / Indications for Use
The AngioJet XPEEDIOR 120 Rheolytic Thrombectomy Catheter is intended for use with the AngioJet System in breaking apart and removing thrombus from:
- infra-inguinal peripheral arteries >= 3.0 mm in diameter,
- upper extremity peripheral veins > 3.0 mm in diameter and
- ilcofemoral and lower extremity veins >= 3.0 mm in diameter.
Product codes (comma separated list FDA assigned to the subject device)
QEZ,KRA
Device Description
When used with the AngioJet System, the XPEEDIOR Rheolytic Thrombectomy Catheter uses high velocity saline jets to percutaneously break-up and remove thrombus. These saline jets are contained within the Catheter and provide the suction that produces this effect.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
infra-inguinal peripheral arteries, upper extremity peripheral veins, ilcofemoral and lower extremity veins
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Applicable preclinical and clinical experience support the expanded indications for use.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.5150 Embolectomy catheter.
(a)
Identification. An embolectomy catheter is a balloon-tipped catheter that is used to remove thromboemboli, i.e., blood clots which have migrated in blood vessels from one site in the vascular tree to another.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/0 description: The image contains two logos. The logo on the left is the Department of Health & Human Services USA logo. The logo on the right is the FDA U.S. Food & Drug Administration logo. The FDA logo has the letters FDA in a blue square.
September 15, 2021
Possis Medical, Inc. Frank Freedman Senior Regulatory Affairs Associate 9055 Evergreen Blvd., N.w. Minneapolis, Minnesota 55433-8003
Re: K071336
Trade/Device Name: XPEEDIOR Rheolytic Thrombectomy Catheter Regulation Number: 21 CFR 870.5150 Regulation Name: Embolectomy catheter Regulatory Class: Class II Product Code: QEZ,KRA
Dear Frank Freedman:
The Food and Drug Administration (FDA) is sending this letter to notify you of an administrative change related to your previous substantial equivalence (SE) determination letter dated August 24. 2007. Specifically, FDA is updating this SE Letter because FDA has created a new product code to better categorize your device technology.
Please note that the 510(k) submission was not re-reviewed. For questions regarding this letter please contact Gregory O'Connell, OHT2: Office of Cardiovascular Devices. (301) 796-6075. Gregory. Oconnell(@FDA.HHS.gov.
Sincerely,
Gregory W. Digitally signed by Gregory W. O'connell -S O'connell -S Date: 2021.09.15
O'connell -S 10:15:22 -04'00'
Gregory O'Connell Assistant Director DHT2C: Division of Coronary and Peripheral Intervention Devices OHT2: Office of Cardiovascular Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
1
Image /page/1/Picture/1 description: The image shows the seal of the Department of Health & Human Services (HHS) of the United States. The seal features a stylized eagle with three lines representing the department's mission. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the eagle.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
AUG 2 4 2007
Possis Medical, Inc. c/o Frank B. Freedman, Ph.D. Senior Regulatory Affairs Associate 9055 Evergreen Boulevard NW Minneapolis, MN 55433-8003
Re: K071336
XPEEDIOR™ Rheolytic Thrombectomy Catheter Regulation Number: 21 CFR 870.5150 Regulation Name: Embolectomy Catheter Regulatory Class: Class II (Two) Product Code: DXE, KRA Dated: July 18, 2007 Received: July 19, 2007
Dear Dr. Freedman:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Iisting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
2
Page 2 - Frank B. Freedman, Ph.D.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as sct forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
una R. Vochner
Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
3
Enclosure
3
Indications for Use
510(k) Number (if known): K071336
Device Name: XPEEDIOR™ Rheolytic Thrombectomy Catheter
Indications For Use:
The AngioJet XPEEDIOR 120 Rheolytic Thrombectomy Catheter is intended for use with the AngioJet System in breaking apart and removing thrombus from:
- infra-inguinal peripheral arteries ≥ 3.0 mm in diameter, ●
- upper extremity peripheral veins > 3.0 mm in diameter and .
- ilcofemoral and lower extremity veins ≥ 3.0 mm in diameter. .
Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
3
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Janna R. Vachner
(Division Sign-Off) Division - Cardiovascular Devices
510(k) Number_K031336
4
5. 510(k) Summary
| Submitter: | Frank B. Freedman, Ph.D.
Possis Medical, Inc.
9055 Evergreen Boulevard, N.W.
Coon Rapids, MN 55433
Phone: 763.780.4555
Fax: 763.780.2227 | | AUG 24 2007 |
|-----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|-------------|
| Contact Person: | Primary Contact
Frank B. Freedman
Possis Medical, Inc. | Secondary Contact
Mark D. Stenoien
Possis Medical, Inc. | |
| Device Common Name: | Thrombectomy Catheter | | |
| Device Trade Name: | XPEEDIORTM Rheolytic Thrombectomy Catheter | | |
| Device Classification Name: | Embolectomy Catheter | | |
| Predicate Devices: | AngioJet XPEEDIOR® Rheolytic™ Thrombectomy Catheter
(K040013, K052256 and K061951) | | |
Device Description
When used with the AngioJet System, the XPEEDIOR Rheolytic Thrombectomy Catheter uses high velocity saline jets to percutaneously break-up and remove thrombus. These saline jets are contained within the Catheter and provide the suction that produces this effect.
Indications for Use
The currently cleared XPEEDIOR Catheter indications for use were expanded to include breaking apart and removing thrombus from:
- . infra-inguinal peripheral arteries > 3.0 mm in diameter,
- . upper extremity peripheral veins > 3.0 mm in diameter and
- . ileofemoral and lower extremity veins > 3.0 mm in diameter."
Comparison to Predicate Devices
No design, packaging, sterilization or other device change was required to expand the AngioJet XPEEDIOR Rheolytic Thrombectomy Catheter indications for use (K040013, K052556 and K061951).
Supporting Information
Applicable preclinical and clinical experience support the expanded indications for use.